Regenxbio IncNASDAQ:RGNX
- LAST PRICE9.7400
- TODAY'S CHANGE (%)0.3900 (4.1711%)
- Bid / Lots9.7200/ 1
- Ask / Lots9.7500/ 2
- Open / Previous Close9.4500 / 9.3500
- Day Range
- 52 Week Range
- Volume162,636
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RGNX |
|---|---|---|
| 09:32 ET | 8918 | 9.495 |
| 09:34 ET | 248 | 9.49 |
| 09:36 ET | 6200 | 9.475 |
| 09:38 ET | 200 | 9.5553 |
| 09:39 ET | 200 | 9.53 |
| 09:41 ET | 2061 | 9.495 |
| 09:43 ET | 400 | 9.505 |
| 09:45 ET | 200 | 9.505 |
| 09:48 ET | 7859 | 9.515 |
| 09:50 ET | 3681 | 9.515 |
| 09:52 ET | 2550 | 9.54 |
| 09:54 ET | 2284 | 9.54 |
| 09:56 ET | 2122 | 9.51 |
| 09:59 ET | 13552 | 9.5 |
| 10:01 ET | 1663 | 9.5076 |
| 10:03 ET | 700 | 9.5 |
| 10:06 ET | 322 | 9.48 |
| 10:08 ET | 400 | 9.49 |
| 10:10 ET | 300 | 9.44 |
| 10:12 ET | 2450 | 9.45 |
| 10:14 ET | 200 | 9.45 |
| 10:15 ET | 600 | 9.485 |
| 10:19 ET | 925 | 9.51 |
| 10:21 ET | 300 | 9.505 |
| 10:24 ET | 616 | 9.49 |
| 10:26 ET | 5300 | 9.475 |
| 10:28 ET | 300 | 9.47 |
| 10:30 ET | 1500 | 9.4498 |
| 10:32 ET | 100 | 9.45 |
| 10:33 ET | 300 | 9.43 |
| 10:35 ET | 210 | 9.425 |
| 10:42 ET | 323 | 9.45 |
| 10:46 ET | 500 | 9.46 |
| 10:48 ET | 1109 | 9.485 |
| 10:50 ET | 100 | 9.5 |
| 10:51 ET | 1800 | 9.52 |
| 10:53 ET | 400 | 9.53 |
| 10:55 ET | 300 | 9.51 |
| 10:57 ET | 500 | 9.5292 |
| 11:00 ET | 1353 | 9.56 |
| 11:02 ET | 200 | 9.595 |
| 11:06 ET | 2425 | 9.63 |
| 11:08 ET | 200 | 9.67 |
| 11:11 ET | 100 | 9.65 |
| 11:13 ET | 100 | 9.68 |
| 11:15 ET | 200 | 9.62 |
| 11:20 ET | 1900 | 9.66 |
| 11:22 ET | 300 | 9.62 |
| 11:24 ET | 500 | 9.6 |
| 11:26 ET | 300 | 9.6 |
| 11:27 ET | 100 | 9.6114 |
| 11:29 ET | 3125 | 9.61 |
| 11:31 ET | 1200 | 9.63 |
| 11:36 ET | 3320 | 9.64 |
| 11:38 ET | 3866 | 9.6 |
| 11:42 ET | 300 | 9.62 |
| 11:44 ET | 100 | 9.62 |
| 11:45 ET | 300 | 9.62 |
| 11:47 ET | 200 | 9.6 |
| 11:49 ET | 2142 | 9.61 |
| 11:51 ET | 200 | 9.57 |
| 11:54 ET | 1943 | 9.53 |
| 11:56 ET | 2110 | 9.5625 |
| 11:58 ET | 1761 | 9.58 |
| 12:00 ET | 700 | 9.58 |
| 12:02 ET | 997 | 9.6 |
| 12:03 ET | 439 | 9.6487 |
| 12:05 ET | 600 | 9.64 |
| 12:07 ET | 3060 | 9.715 |
| 12:09 ET | 1852 | 9.77 |
| 12:12 ET | 650 | 9.72 |
| 12:16 ET | 5960 | 9.75 |
| 12:18 ET | 100 | 9.74 |
| 12:20 ET | 200 | 9.74 |
| 12:21 ET | 3000 | 9.74 |
| 12:25 ET | 2400 | 9.735 |
| 12:27 ET | 200 | 9.74 |
| 12:30 ET | 275 | 9.74 |
| 12:32 ET | 100 | 9.72 |
| 12:34 ET | 730 | 9.74 |
| 12:36 ET | 325 | 9.74 |
Sep 23, 2024
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference, from 4:05PM ET on Monday Sep 23, 2024 by Dow Jones
4:05PM ET on Monday Sep 23, 2024 by Dow Jones
Sep 17, 2024
DJ Regenxbio Names Chan Finance Chief as Vasista Departs, from 7:53AM ET on Tuesday Sep 17, 2024 by Dow Jones
7:53AM ET on Tuesday Sep 17, 2024 by Dow Jones*DJ REGENXBIO Appoints Mitchell Chan As Chief Financial Officer >RGNX, from 7:05AM ET on Tuesday Sep 17, 2024 by Dow Jones
7:05AM ET on Tuesday Sep 17, 2024 by Dow JonesREGENXBIO Appoints Mitchell Chan as Chief Financial Officer, from 7:05AM ET on Tuesday Sep 17, 2024 by Dow Jones
7:05AM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 4, 2024
DJ REGENXBIO Price Target Maintained With a $39.00/Share by HC Wainwright & Co., from 12:46PM ET on Wednesday Sep 04, 2024 by Dow Jones
12:46PM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regenxbio Inc | 462.1M | -1.8x | --- |
SAGE Therapeutics Inc | 426.7M | -0.9x | --- |
Grail Inc | 390.3M | -0.1x | --- |
Alector Inc | 410.7M | -2.5x | --- |
Urogen Pharma Ltd | 521.4M | -3.9x | --- |
Y-mAbs Therapeutics Inc | 602.6M | -24.7x | --- |
Company Information
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Contact Information
- Headquarters
- 9804 Medical Center DriveROCKVILLE, MD, United States 20850
- Phone
- 240-552-8181
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Kenneth Mills
- President, Chief Executive Officer, Director
- Curran Simpson
- Chief Financial Officer, Executive Vice President, Principal Accounting Officer
- Mitchell Chan
- Executive Vice President, Chief Scientific Officer
- Olivier Danos
- Executive Vice President, Chief Legal Officer
- Patrick Christmas
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $462.1M |
|---|---|
Revenue (TTM) | $89.0M |
Shares Outstanding | 49.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.22 |
EPS | $-5.27 |
Book Value | $7.08 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 5.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -279.37% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
